This is going to be a big year in biotech, with a host of drugs set to undergo U.S. Food and Drug Administration (FDA) scrutiny. While picking up an exposure in anticipation of the agency’s decision is a risky strategy, it can also be a rewarding one. This said, here are four companies with promising candidates that all have dates with the FDA this year.
